Left Ventricular Ejection Fraction and the Future of Heart Failure Phenotyping
Matthew Dimond, Nasrien E. Ibrahim, Mona Fiuzat, John J.V. McMurray, JoAnn Lindenfeld, Tariq Ahmad, Biykem Bozkurt, Michael R. Bristow, Javed Butler, Peter E. Carson, G. Michael Felker, Mariell Jessup, Jaime Murillo, Toru Kondo, Scott D. Solomon, William T. Abraham, Christopher M. O’Connor, Mitchell A. Psotka
Abstract
Heart failure (HF) is a complex syndrome traditionally classified by left ventricular ejection fraction (LVEF) cutpoints. Although LVEF is prognostic for risk of events and predictive of response to some HF therapies, LVEF is a continuous variable and cutpoints are arbitrary, often based on historical clinical trial enrichment decisions rather than physiology. Holistic evaluation of the treatment effects for therapies throughout the LVEF range suggests the standard categorization paradigm for HF merits modification. The multidisciplinary Heart Failure Collaboratory reviewed data from large-scale HF clinical trials and found that many HF therapies have demonstrated therapeutic benefit across a large range of LVEF, but specific treatment effects vary across that range. Therefore, HF should practically be classified by association with an LVEF that is reduced or not reduced, while acknowledging uncertainty around the precise LVEF cutpoint, and future research should evaluate new therapies across the continuum of LVEF.